| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $43.4M | — | +108.7% |
| Cost of Revenue | $65.4M | — | +127.5% |
| R&D Expense | $55K | — | -86.3% |
| SG&A Expense | $44.1M | — | +145.4% |
| Operating Income | -$66.1M | — | -151.3% |
| Net Income | -$166.2M | — | -1527.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $224.1M | -51.2% | — |
| Short-term Investments | $449.5M | +47.4% | — |
| Accounts Receivable | $22.0M | -33.3% | — |
| Current Assets | $774.4M | -9.4% | — |
| Total Assets | $1.20B | -1.3% | — |
| Current Liabilities | $89.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$67.3M | — | -60.7% |
| Investing Cash Flow | -$166.0M | — | -9602.3% |
| Financing Cash Flow | -$1.1M | — | -102.1% |
| +51.9% |
| — |
| Long-term Debt | $0 | — | — |
| Total Liabilities | $150.1M | -59.3% | — |
| Stockholders' Equity | -$1.39B | -13.2% | -61.7% |